ChipDX Developing Colon, Breast, Lung, and Tissue-of-Origin Tests for Affymetrix Arrays

The New York-based molecular diagnostics firm is moving ahead with plans to eventually debut at least four microarray-based tests for the clinical market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.